Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
BEAM
STRONG SELLBeam Therapeutics Inc. · Healthcare · United States · $2.6B · Avg Vol: $67M/d
COMPANY DESCRIPTION
Beam Therapeutics Inc. is a leading biotechnology company pioneering the development of precision genetic medicines using its proprietary base editing technology. This novel gene-editing platform enables targeted, single-base changes to DNA without cutting the double helix, offering a potential path to cure a wide range of genetic diseases. Beam holds a significant competitive advantage through its foundational intellectual property and broad pipeline, aiming for transformative therapeutic impact.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 60.9M | 377.7M | 63.5M | 139.7M | 31.9% | 164.0M | 78.9M | 96.1M | -17.1% |
| EPS | -4.13 | -1.72 | -4.58 | -0.81 | — | -0.47 | — | — | — |
| Shares | 71.3M | 81.6M | 83.6M | 101.7M | +42.8% | 102.9M | — | — | — |
| Debt | 179.0M | 172.7M | 161.4M | 154.1M | -4.9% | 250.8M | — | — | — |
| Equity | 733.5M | 981.3M | 733.5M | 1.2B | 19.1% | — | — | — | — |
| Op CF | 22.5M | -149.2M | -347.2M | -345.1M | — | -369.7M | — | — | — |
| Inv CF | -461.3M | 71.8M | 185.0M | -121.4M | — | — | — | — | — |
| Fin CF | 111.6M | 276.4M | 7.7M | 478.0M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of BEAM are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| BEAM | Beam Therapeutics Inc.(you) | $2.6B | 18 | STRONG SELL |
| IMNM | Immunome, Inc. | $2.5B | 17 | STRONG SELL |
| BHVN | Biohaven Ltd. | $2.2B | 19 | STRONG SELL |
| NKTR | Nektar Therapeutics | $2.4B | 21 | SELL |
| MLYS | Mineralys Therapeutics, Inc. | $2.4B | 15 | STRONG SELL |
| IRON | Disc Medicine, Inc. | $2.8B | 22 | SELL |
| CLDX | Celldex Therapeutics, Inc. | $2.8B | 23 | SELL |
| PGEN | Precigen, Inc. | $1.9B | 17 | STRONG SELL |
| KOD | Kodiak Sciences Inc. | $2.6B | 26 | SELL |
| COAG | Hemab Therapeutics Holdings, Inc. | $2.2B | 13 | STRONG SELL |
Peer medians: ROE -25.6% · P/E 27.7x · Gross margin 50.7%